Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.
Sales of a key product line will likely be flat this quarter and next, company management said.
Boston Scientific stock has more questions than answers. Shares of the medical device maker dropped have about 14% this week to about $49 after management said growth of its Watchman product, an implant that reduces the risk of stroke in patients with non-valvular atrial fibrillation (AFib), is slowing. The company stood by its financial guidance, but the market clearly has larger concerns.
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
Boston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl
Investing.com -- Wells Fargo has downgraded Boston Scientific to “Equal Weight” from “Overweight,” citing growing uncertainty around the medical device maker’s two key growth drivers — its electrophysiology (EP) business and the Watchman heart implant franchise.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
Investors have recently become less willing to tolerate compressed margins tied to rising costs and slowing demand.
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to buy right now. On May 19, TD Cowen reiterated its Buy rating and $80 price target on Boston Scientific Corporation (NYSE:BSX). TD Cowen constructed its thesis around Boston Scientific’s Fracture IDE study. The study tested the company’s SEISMIQ 4CE Coronary Intravascular Lithotripsy […]
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
US equity indexes were higher on Wednesday after a decline in crude oil prices and government bond y
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.
Zscaler (ZS) shares plunged 31% intraday after the company issued a fiscal Q4 revenue outlook that m
Boston Scientific's CEO stated that the company will update its three-year plan, including targets for FY27 and FY28, after the third-quarter earnings call.
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
Investing.com -- Boston Scientific Corp (NYSE:BSX) fell over 6% Wednesday after management lowered its full-year guidance during a presentation at Bernstein.
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
Boston Scientific Corporation (NYSE:BSX) is one of the best medical stocks to invest in according to billionaires. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in […]
Boston Scientific (NYSE:BSX) has initiated two voluntary recalls of its LUX-Dx II arrhythmia detector and alarm devices. The recalls follow FDA enforcement reports citing failures in data collection and monitoring of critical cardiac events for certain patients. Issues include discrepancies in device programming interfaces that affect reliability of arrhythmia monitoring and treatment decisions. The recalls are ongoing and affect patients and clinicians in multiple regions, including the US...
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
